The top two spots continue to go to the same two in our domestic ETFs that have held onto these positions since January, notes Jim Lowell in The Forbes ETF Advisor.
First Trust US IPO (FPX) seeks investment results that correspond to the price and yield performance of the IPOX-100 US Index, which is made up of 100 largest, best performing, most liquid US initial public offerings—measuring the IPO's performance during their first 1,000 trading days.
IPOs get placed into the index on their sixth trading day and remain in the index for 1000 days. It began trading in April 2006, and has a market value of over $75 million.
The top three sectors are consumer discretionary (25.6%), energy (18.8%), and health care (17.3%).
PowerShares Dynamic Large Cap Value (PWV) seeks investment results that correspond to the price and yield performance of the Dynamic Large Cap Value Intellidex Index, which seeks to provide capital appreciation while maintaining large cap value exposure.
It began trading in March 2005, and has a market value of approximately $570 million. The top three sectors are financials (28.6%), health care (18.8%), and information technology (15.7%).
The top ten holdings are Pfizer, Verizon, Johnson & Johnson, Cisco, Wal-Mart, AT&T, Wells Fargo, Exxon Mobil, ConocoPhillips, and Microsoft.
Meanwhile, the PowerShares Dynamic Pharmaceuticals (PJP) has grabbed the top spot among sector ETFs.
The fund seeks investment results that correspond to the price and yield performance of the Dynamic Pharmaceuticals Intellidex Index, which is made up of 30 US companies involved in the research, development, production, sale, or distribution of pharmaceuticals and drugs.
It began trading in June 2005, and has a market value of $530 million. Credit the active management index construction for (PJP's) rise in our rankings.
The top sectors are health care (97.3%), and consumer staples (2.7%). The top ten holdings are Pfizer, Johnson & Johnson, Merck & Co, Bristol-Myers Squibb, Amgen, Abbott Labs, Eli Lilly, Gilead Sciences, Questcor Pharmaceuticals, and Ligand Pharmaceuticals.
Subscribe to The Forbes ETF Advisor here…
More from MoneyShow.com:
